Three independent discounted-cash-flow-style models value Xeris Biopharma Holdings, Inc. Common Stock every trading day. 1 of 3 currently price XERS above its market price.
| Free Cash Flow model | $-20.30 |
| Excess Profit model | $-29.19 |
| Residual Earnings model | $69.84 |
| Dividend Discount model | — |
| Piotroski F-Score | 7 / 9 |
| Return on invested capital | +8.4% |
| Net debt / EBITDA | 4.4× |
| Gross margin | +100.0% |
| Revenue CAGR | +38.3% |
| Cash conversion | 51.7× |
| Dividend yield | — |
| Buyback yield | -9.3% |
These are StockKitty's default assumptions. In the app, the models recompute live as you adjust growth, discount rates, and margins — and the AI explains the bull case, bear case, and quality picture.
Open XERS in StockKitty